FDA Approves Talazoparib With Enzalutamide For Metastatic Androgen Pathway Modulation-Naive Or -Sensitive Prostate Cancer With HRR Gene Mutations

뉴스 본문을 불러오고 있어요.

FDA Approves Talazoparib With Enzalutamide For Metastatic Androgen Pathway Modulation-Naive Or -Sensitive Prostate Cancer With HRR Gene Mutations | 웨이프 WAPE

FDA Approves Talazoparib With Enzalutamide For Metastatic Androgen Pathway Modulation-Naive Or -Sensitive Prostate Cancer With HRR Gene Mutations

기사 요약

관련 종목

댓글 —